To assess the effectiveness of Covid-19 vaccines with respect to laboratory-confirmed SARS-CoV-2 infection–associated hospitalizations, ICU admissions, or visits to emergency departments or urgent care clinics
Latest Information Update: 16 Sep 2021
At a glance
- Drugs Ad26.COV2 S (Primary) ; Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
- Focus Therapeutic Use
- 16 Sep 2021 New trial record
- 08 Sep 2021 Results published in the New England Journal of Medicine